The retail price of Lantus insulin without insurance can vary significantly, but it typically falls within the range of $300 to over $500 for a 10-milliliter vial [1].
How Much Does Lantus Cost Without Insurance?
The cost of Lantus insulin, a long-acting insulin used to treat type 1 and type 2 diabetes, is considerably higher for individuals without prescription drug coverage. Prices can fluctuate based on the pharmacy, location, and specific dosage or pen formulation. For example, a single 10 mL vial of Lantus Solostar may cost around $300-$350, while other quantities or pen injector options could range from $400 to over $500 per package [1].
What Factors Influence Lantus Pricing?
Several elements contribute to the fluctuating cost of Lantus. These include the list price set by the manufacturer, Sanofi, as well as pharmacy markups and potential discounts offered by specific drugstores or through patient assistance programs. The complexity of the pharmaceutical supply chain and market dynamics also play a role [1].
Are There Cheaper Alternatives to Lantus?
For those seeking lower-cost options, biosimilar versions of insulin glargine, the active ingredient in Lantus, have become available. For instance, biosimilars like Semglee and Rezvoglar offer similar therapeutic effects at a reduced price point compared to the branded Lantus. Additionally, generic versions of insulin glargine are also emerging, which could further decrease costs for patients [2].
Can I Get Lantus at a Lower Price with Savings Cards or Programs?
Manufacturers often provide savings cards or patient assistance programs designed to reduce out-of-pocket expenses for eligible individuals. Sanofi, the maker of Lantus, offers a Lantus® SoloSTAR® Savings Card that can lower the cost for commercially insured patients [3]. For uninsured or underinsured patients, Sanofi may also have patient assistance programs that can provide medication at a reduced cost or free of charge based on income and other eligibility criteria [4].
When Does Lantus Patent Expiration Affect Pricing?
The patent exclusivity for Lantus has largely expired, paving the way for the introduction of biosimilar and generic alternatives. This competition generally leads to a decrease in the overall cost of insulin glargine products in the market. Information on specific patent expiration dates for various formulations of Lantus can be found through resources like DrugPatentWatch.com [5].
What is the Difference Between Lantus and its Biosimilars?
Lantus is a brand-name biologic medication. Biosimilars, such as Semglee and Rezvoglar, are highly similar to Lantus and have been shown to have no clinically meaningful differences in terms of safety, purity, and potency. They are approved for the same indications as Lantus. The primary difference lies in their cost, with biosimilars typically being less expensive than the originator product [2].
Sources:
[1] GoodRx. (n.d.). Lantus Price Comparison. Retrieved from https://www.goodrx.com/lantus
[2] FDA. (2022, July 19). Biosimilarity. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilarity
[3] Lantus. (n.d.). Lantus Savings Card. Retrieved from https://www.lantushcp.com/savings-and-support/savings-card
[4] Sanofi Patient Access Programs. (n.d.). Retrieved from https://www.sanofipatientaccess.com/
[5] DrugPatentWatch. (n.d.). Lantus Patent Information. Retrieved from https://drugpatentwatch.com/